Tag: Pharmacology updates

While the FDA approved generic versions of Eliquis back in 2019, various patent litigation and extensions have consistently delayed their market entry. Patients and healthcare providers frequently ask, "Is Eliquis going to be generic in 2025?", and the current answer, due to ongoing legal battles, is no. The earliest expected launch date for generic apixaban in the U.S. is now estimated to be in 2028, with similar delays affecting European markets.

Despite its long history as a household staple, evidence shows that using hydrogen peroxide on wounds can damage healthy tissue and delay healing. While the fizzing action was once seen as a sign of effective cleaning, medical experts now recommend safer and more effective alternatives for proper wound care.

In August 2023, the FDA approved Zurzuvae (zuranolone) for postpartum depression, marking one of the most recent and novel pharmacological advancements related to anxiety and depression. This development, alongside breakthrough designations for compounds like MM-120, indicates a new era for what is the newest anti-anxiety drug, moving beyond traditional classes toward more targeted approaches.